219 related articles for article (PubMed ID: 23183440)
1. Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Wohl DA; Dumond JB; Blevins S; Pittard D; Ragan D; Wang R; Massengale K; Walsh K; Floris-Moore M; Eron JJ; Richardson A; Hudgens MG; Kashuba AD
Antimicrob Agents Chemother; 2013 Feb; 57(2):784-8. PubMed ID: 23183440
[TBL] [Abstract][Full Text] [Related]
2. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
3. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
4. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
6. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
[TBL] [Abstract][Full Text] [Related]
7. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Nishijima T; Gatanaga H; Shimbo T; Komatsu H; Endo T; Horiba M; Koga M; Naito T; Itoda I; Tei M; Fujii T; Takada K; Yamamoto M; Miyakawa T; Tanabe Y; Mitsuya H; Oka S;
PLoS One; 2013; 8(8):e73639. PubMed ID: 23951362
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ; Rockstroh JK; Reynes J; Andrade-Villanueva J; Ramalho-Madruga JV; Bekker LG; Young B; Katlama C; Gatell-Artigas JM; Arribas JR; Nelson M; Campbell H; Zhao J; Rodgers AJ; Rizk ML; Wenning L; Miller MD; Hazuda D; DiNubile MJ; Leavitt R; Isaacs R; Robertson MN; Sklar P; Nguyen BY;
Lancet Infect Dis; 2011 Dec; 11(12):907-15. PubMed ID: 21933752
[TBL] [Abstract][Full Text] [Related]
11. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
[TBL] [Abstract][Full Text] [Related]
14. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
15. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Bedimo RJ; Drechsler H; Jain M; Cutrell J; Zhang S; Li X; Farukhi I; Castanon R; Tebas P; Maalouf NM
PLoS One; 2014; 9(8):e106221. PubMed ID: 25170938
[TBL] [Abstract][Full Text] [Related]
16. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A;
Lancet; 2014 Nov; 384(9958):1942-51. PubMed ID: 25103176
[TBL] [Abstract][Full Text] [Related]
17. Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy.
Young L; Wohl DA; Hyslop WB; Lee YZ; Napravnik S; Wilkin A
HIV Clin Trials; 2015 Oct; 16(5):163-9. PubMed ID: 26249671
[TBL] [Abstract][Full Text] [Related]
18. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
[TBL] [Abstract][Full Text] [Related]
19. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]